The global anti-aging market is worth billions of dollars with significant growth potential. Here’s a list of some of the anti-aging stocks looking to capitalize on that growth.
As the global population continues to get older, the popularity of anti-aging stocks is also rising thanks to advancements in technology and research on human longevity.
The desire to increase life quality and expectancy drives the top anti-aging stocks in the life science space as they pursue technologies and therapies aimed at slowing the aging process and preserving health.
According to Research and Markets, revenue from the global anti-aging market is projected to be worth a staggering US$64.04 billion by 2026, up from US$44.12 billion in 2020; it is seen growing at a compound annual growth rate of 6.1 percent during the forecast period, even with the impact of COVID-19.
The research firm attributes this growth to new anti-aging treatments and products brought about by advancements in technology and increased investments in research and development, as well as higher demand for anti-aging products and devices from both young and older consumers.
Below is a brief overview of five anti-aging stocks on the NYSE and NASDAQ with market caps between US$50 million and US$500 million. All figures were current as of July 22, 2021.
1. Lineage Cell Therapeutics (NYSEAMERICAN:LCTX)
Market cap: US$401.95 million; current share price: US$2.68
First on this list of anti-aging stocks, Lineage Cell Therapeutics works in the fields of regenerative medicine, human embryonic stem cell technology and induced pluripotent stem cell technology. It develops therapies that are based on stem cell biology and are intended to rebuild cell and tissue function lost due to degenerative diseases and injury.
In the company’s stem cell programs are: OpRegen, which is a cell replacement therapy in a Phase 2a clinical trial to treat advanced dry age-related macular degeneration; OPC1, which has completed Phase 2a clinical trials and is now in the planning phases for Phase 2b/3 trials for acute spinal cord injuries; and VAC2, which is in a Phase 1 clinical trial in patients with non-small-cell lung cancer.
2. Frequency Therapeutics (NASDAQ:FREQ)
Market cap: US$269.65 million; current share price: US$7.88
Frequency Therapeutics is a biotechnology company developing treatments related to hearing loss. Its lead product candidate is FX-322, and it hones in on sensorineural hearing loss. A number of Phase 1 to 2 trials are ongoing for various degrees of hearing loss, with topline results expected in H2 2021.
Looking further ahead, Frequency Therapeutics is also advancing preclinical research efforts aimed at repairing neurological damage in patients with multiple sclerosis.
3. Unity Biotechnology (NASDAQ:UBX)
Market cap: US$211.19 million; current share price: US$3.85
Unity Biotechnology’s mission statement revolves around prolonging the human lifespan. The company’s primary goal is to slow down or reverse age-related conditions and improve health. The lead product candidates in the company’s pipeline are UBX1325 and UBX1967, both of which are being tested as possible treatments for age-related diseases in the eye, such as age-related macular degeneration, diabetic macular edema and proliferative diabetic retinopathy.
UBX1325 is currently in Phase 2a trials, with data expected in the first half of 2022, while UBX1967 is undergoing pre-clinical trials. Unity’s pipeline also includes neurology programs aimed at neurodegenerative diseases and cognitive disorders.
4. CohBar (NASDAQ:CWBR)
Market cap: US$71.67 million; current share price: US$1.16
CohBar is taking a different approach to age-related disease through the research and development of mitochondria-based therapeutics, an emerging class of drugs. A novel group of peptides encoded within the mitochondrial genome has been shown to regulate metabolism and cell death.
These treatments have the potential to target diseases related to aging and metabolic dysfunction, such as non-alcoholic steatohepatitis, obesity, type 2 diabetes, cancer, cardiovascular diseases and central nervous system conditions. The company expects to release data in Q3 2021 for its Phase 1a/1b clinical study of CB4211 for the potential treatment of nonalcoholic steatohepatitis and obesity.
5. AgeX Therapeutics (NYSEAMERICAN:AGE)
Market cap: US$58.04 million; current share price: US$1.53
Last on this list of anti-aging stocks is AgeX Therapeutics, a biotechnology company developing medical therapeutics related to human longevity. Its proprietary induced tissue regeneration longevity platform and PureStem technology are designed to aid in the development of medicines that address aging-related health concerns by harnessing the regenerative capacity of cells.
In early 2021, AgeX announced a research collaboration with Ohio State University. The company’s brown adipocyte tissue cell therapy candidate, called AgeX-BAT1, will be used in mice to determine whether transplantation of AgeX-BAT1 cells may improve diet-induced obesity and metabolic health, including glucose metabolism and cardiac function.
This is an updated version of an article originally published by the Investing News Network in 2017.
Don’t forget to follow us @INN_LifeScience for real-time news updates.
Securities Disclosure: I, Melissa Pistilli, hold no direct investment interest in any company mentioned in this article.